Peninsula Asset Management Inc. Increases Stock Holdings in Stryker Corporation $SYK

Peninsula Asset Management Inc. grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 15.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,817 shares of the medical technology company’s stock after purchasing an additional 2,839 shares during the quarter. Stryker comprises approximately 3.5% of Peninsula Asset Management Inc.’s portfolio, making the stock its 9th biggest holding. Peninsula Asset Management Inc.’s holdings in Stryker were worth $6,840,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of SYK. Norges Bank bought a new stake in shares of Stryker in the fourth quarter valued at approximately $1,822,272,000. Auto Owners Insurance Co boosted its holdings in Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after buying an additional 2,906,448 shares during the period. Wellington Management Group LLP grew its stake in Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC grew its stake in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after buying an additional 1,146,998 shares in the last quarter. Finally, Credit Agricole S A bought a new stake in Stryker during the 3rd quarter valued at $194,045,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $316.46 on Thursday. The company’s 50 day simple moving average is $311.28 and its two-hundred day simple moving average is $337.10. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The stock has a market capitalization of $121.32 billion, a PE ratio of 36.63, a P/E/G ratio of 1.99 and a beta of 0.77.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last ninety days. 4.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Leerink Partners dropped their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Sanford C. Bernstein set a $410.00 price target on Stryker in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, BMO Capital Markets initiated coverage on Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.